Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.

Abstract

Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have an inherent tendency to progress to acute myeloid leukemia (AML). Using high-resolution SNP microarrays, we studied a total of 517 MPN and MDS patients in different disease stages, including 77 AML cases with previous history of MPN (N = 46) or MDS (N = 31). Frequent chromosomal deletions of variable sizes were detected, allowing the mapping of putative tumor suppressor genes involved in the leukemic transformation process. We detected frequent deletions on the short arm of chromosome 6 (del6p). The common deleted region on 6p mapped to a 1.1-Mb region and contained only the JARID2 gene--member of the polycomb repressive complex 2 (PRC2). When we compared the frequency of del6p between chronic and leukemic phase, we observed a strong association of del6p with leukemic transformation (P = 0.0033). Subsequently, analysis of deletion profiles of other PRC2 members revealed frequent losses of genes such as EZH2, AEBP2, and SUZ12; however, the deletions targeting these genes were large. We also identified two patients with homozygous losses of JARID2 and AEBP2. We observed frequent codeletion of AEBP2 and ETV6, and similarly, SUZ12 and NF1. Using next generation exome sequencing of 40 patients, we identified only one somatic mutation in the PRC2 complex member SUZ12. As the frequency of point mutations in PRC2 members was found to be low, deletions were the main type of lesions targeting PRC2 complex members. Our study suggests an essential role of the PRC2 complex in the leukemic transformation of chronic myeloid disorders.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Carrier Proteins / genetics
  • Cell Transformation, Neoplastic / genetics*
  • Chromosome Aberrations
  • Chromosome Deletion*
  • Chromosome Mapping
  • Chromosomes, Human, Pair 6 / genetics
  • Chromosomes, Human, Pair 6 / ultrastructure*
  • DNA-Binding Proteins / deficiency
  • DNA-Binding Proteins / genetics
  • Disease Progression
  • Enhancer of Zeste Homolog 2 Protein
  • Female
  • Genes, Tumor Suppressor*
  • Genotype
  • Humans
  • Leukemia, Myeloid / genetics
  • Male
  • Myelodysplastic Syndromes / genetics*
  • Myeloproliferative Disorders / genetics*
  • Neoplasm Proteins / deficiency
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Nerve Tissue Proteins / deficiency
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / physiology*
  • Nuclear Proteins / deficiency
  • Nuclear Proteins / genetics
  • Oligonucleotide Array Sequence Analysis
  • Polycomb Repressive Complex 2
  • Polycomb-Group Proteins
  • Repressor Proteins / deficiency
  • Repressor Proteins / genetics
  • Repressor Proteins / physiology
  • Sequence Analysis, DNA
  • Transcription Factors / deficiency
  • Transcription Factors / genetics
  • Tumor Suppressor Proteins / deficiency
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / physiology*

Substances

  • AEBP2 protein, human
  • Carrier Proteins
  • DNA-Binding Proteins
  • JARID2 protein, human
  • Neoplasm Proteins
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • PHF19 protein, human
  • Polycomb-Group Proteins
  • Repressor Proteins
  • SUZ12 protein, human
  • Transcription Factors
  • Tumor Suppressor Proteins
  • EZH1 protein, human
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2